AG-DESVENLAFAXINE TABLET (EXTENDED-RELEASE)
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
28-02-2022
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
から入手可能:
ANGITA PHARMA INC.
ATCコード:
N06AX23
INN（国際名）:
DESVENLAFAXINE
投薬量:
50MG
医薬品形態:
TABLET (EXTENDED-RELEASE)
構図:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50MG
投与経路:
ORAL
パッケージ内のユニット:
100
処方タイプ:
Prescription
製品概要:
Active ingredient group (AIG) number: 0152509001; AHFS:
認証ステータス:
APPROVED
承認日:
2022-03-04
製品の特徴
PRODUCT MONOGRAPH
Pr
AG-DESVENLAFAXINE
Desvenlafaxine Extended-Release Tablets
50 and 100 mg desvenlafaxine (as desvenlafaxine succinate monohydrate)
Antidepressant
Angita Pharma Inc.
1310 rue Nobel
Boucherville, Québec
J4B 5H3
SUBMISSION CONTROL NO.: 260512
_AG-DESVENLAFAXINE (desvenlafaxine succinate) Product Monograph _
_Page 1 of 57_
Date of Revision:
February
28, 2022
_AG-DESVENLAFAXINE (desvenlafaxine succinate) Product Monograph_
_Page 2 of 57_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION.
.............................................................. 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................3
CONTRAINDICATIONS
......................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
13
DRUG INTERACTIONS
....................................................................................................24
DOSAGE AND ADMINISTRATION
................................................................................28
OVERDOSAGE
...................................................................................................................
31
ACTION AND CLINICAL PHARMACOLOGY
...............................................................33
STORAGE AND STABILITY
............................................................................................37
SPECIAL HANDLING INSTRUCTIONS
..........................................................................
37
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................37
PART II: SCIENTIFIC INFORMATION
..................................................................................
完全なドキュメントを読む
